Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Posts Earnings Results, Misses Expectations By $0.10 EPS

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10), Zacks reports.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.06 on Monday, reaching $0.22. The company’s stock had a trading volume of 828,332 shares, compared to its average volume of 7,485,027. The firm has a market capitalization of $519,978.00 and a P/E ratio of -0.05. The business has a 50-day simple moving average of $0.99. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, HC Wainwright initiated coverage on shares of Lakewood-Amedex Biotherapeutics in a report on Wednesday, October 28th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Lakewood-Amedex Biotherapeutics presently has a consensus rating of “Hold”.

Read Our Latest Stock Report on Lakewood-Amedex Biotherapeutics

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Featured Articles

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.